Location: 7 Days Live Virtual Class Room
Dates: April 19-25, 2021
Live Course Fee: $1,350.00
Add To CartRegister for both Live and Online Course and save!
7-Day Live Virtual Classroom Board Review: Focusing on NAPLEX® and the clinical pharmacy portion of CPJE (No Law). This is a live streaming class with the participants and speakers all in a virtual classroom where participants can see and interact with the instructors during the 7-day review. The registration deadline to receive course books on time is April 12th.
Note: Due to time constraints, not all the topics covered in the course book and online course can be covered during the live review. We, therefore, recommend the BUNDLE COURSE for most students, which, in addition to the live sessions, provides 12 months of access to all the prerecorded video-lectures.
Coursebook: 700 pages of FOCUSED, HIGH YIELD material accompanying the lectures. No fluff, no unnecessary information. You will recive your course book within 7 business days.
Question Bank: 2500 online question bank with detailed explanations and patient profile cases
Chart Book: 100-page Chart book to help with the memorization of details.
Support: Pharmacy board experts, Dr. Yavari & Dr. Miremadi's support and assistance via email for one year.
April 19 - 25, 2021 Live Course Dates & Hours (PST):
April 19 - Monday 8 AM - 6 PM Pacific Standard Time
April 20 - Tuesday 8 AM - 6 PM Pacific Standard Time
April 21 - Wednesday 8 AM - 6 PM Pacific Standard Time
April 22 - Thursday 8 AM - 6 PM Pacific Standard Time
April 23 - Friday 8 AM - 6 PM Pacific Standard Time
April 24 - Saturday 8 AM - 6 PM Pacific Standard Time
April 25 - Sunday 8 AM - 6 PM Pacific Standard Time
Note: NO LAW lectures: The 7-day Live board review is solely CLINICAL pharmacy lectures for NAPLEX and the Clinical portion of CPJE. The Law portion of CPJE is covered by CA Law Online Course.
Access to Online Question Bank is included with the Live course: 2500 Board-type questions with answers, detailed explanations & patient profile cases to solidify your understanding of the material.
The questions are formatted to include patient profiles, fill in the blank calculations, and standard multiple choice questions.
Progress Tracking allows you to follow and manage your question bank results, and evaluate your progress on your user dashboard. At the end of your study, we have two comprehensive practice tests to conclude the material that has been covered.
R.N., a 56-year-old male, presents to the ER with progressively worsening shortness of breath at rest, fatigue, and bilateral pitting edema of his legs for the last few months. He has a history of diabetes and long-standing hypertension.
Current Medications:
Metformin 1000 mg PO BID
Pioglitazone 30 mg PO QD
Hydrochlorothiazide 25 mg PO QD
Lisinopril 40 mg PO QD
Amlodipine 10 mg PO QD
Vitals: BP: 110/63 mmHg P: 110, Resp Rate: 26 Temp: 97.8
Labs:
BUN ................................ 19 mg/dL
Serum Creatinine ............ 1.1 mg/dL
Potassium ....................... 3.1 mEq/L
BNP ................................ 960 (10 - 300)
Troponins ....................... Negative
Chest x-ray .................... Enlarged cardiac silhouette, mild pulmonary edema
Echo: EF ...................... 32%
Which of his medications may be worsening his pulmonary edema and leg edema symptoms? Select ALL that apply.
A.J is a 49-year-old male with history of liver cirrhosis. He is brought in to ER by family members with chief complaint of confusion and altered mental status for the last 24 hours. On exam, A.J is difficult to arouse; he is not oriented to time, person or place.
Vitals: BP: 110/67 mmHg P: 80 RR: 14 Temp 98.6
Labs:
Na+ ………………….. 135 mEq/L
K+ …………………… 4.2 mEq/L
Albumin ……………. 2.0 g/dL
ALT …………………. 60 U/L
AST …………………. 56 U/L
Ammonia …………... 110 (15 – 45 mcg/dL)
INR …………………. 2.1
Urine analysis & Lumbar puncture results are normal.
Which of the following treatment measures do you recommend?
Select ALL that apply:
D.B is a 67-year-old male with ESRD on dialysis who has been on Epogen 3000 units SC three times a week for anemia of chronic renal failure. His recent labs are as follows:
Hgb …………………. 12.6 g/dL (13.5 – 16.5 g/dL for males)
Hct …………………… 38.6 % (40% – 52%)
MCV …………………. 86 fL
WBC ………………… 4.0 thous/microL
Platelets …………….. 185 thous/microL
With regards to his Epogen dosing, what would be the most appropriate course of action?
Which of the following medications are used to treat hyperphosphotemia of ESRD? Select ALL that apply.
Which of the following is NOT a suspending agent?
Due to time constraints, some of the topics covered in the course book and online course will not be lectured on during the Live Review.
Hypertension Hypertensive emergency Congestive Heart Failure Atrial Fibrillation Anti-Arrhythmics Anti-Coagulants Anti-platelets Thrombolytics Stroke Angina Acute Coronary Syndrome Myocardial Infarction Autonomic Nervous System Dyslipidemia LABS Electrolytes Metabolic panels Renal and Hepatic dysfunction CBC and Anemias Asthma & COPD Nebulizers and MDIs Diabetes Mellitus Chemotherapy Osteoporosis Contraceptives Womens' health Rheumatoid Arthritis GERD / PUD Pregnancy Smoking Cessation Pain Management Muscle Relaxants Insomnia About the boards |
Patient Profiles / Inpatient cases Calculations Statistics Compounding IV Incompatibilities TPN Ulcerative Colitis Crohn's disease Irritable Bowel Syndrome Multiple Sclerosis Transplant Drugs Antibiotics Antivirals Antifungals Tuberculosis HIV / AIDS Immunizations Anxiety and related disorders Depression Bipolar disorder Schizophrenia Parkinson's CNS Stimulants Weight loss Alzheimer's Migraine Seizure Gout Herbals OTC Thyroid Meds Ophthalmic Meds Cystic Fibrosis Sickle Cell Disease Erectile Dysfunction
|